Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and T...( In SPIRIT II Trial XIENCE V ...),Health

In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presented today from Abbott's (NYSE: ABT) SPIRIT II clinical trial demonstrated that the clinical advantages of the XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase between two and three years compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS). Both TAXUS Express2 (73 percent of lesions) and TAXUS Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial. The data also showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. The results from the SPIRIT II trial were presented during the i2 Summit at the American College of Cardiology's 58th annual scientific session in Orlando, Fla.

Between two and three years, Abbott's market-leading XIENCE V maintained a low cardiac death rate of 0.5 percent, while the observed cardiac death rate for TAXUS more than tripled during the same time period (1.3 percent at two years vs. 4.2 percent at three years)*. Similarly, XIENCE V maintained a low, single-digit rate of major adverse cardiac events (MACE) between two and three years (6.4 percent at two years vs. 6.4 percent at three years), while the observed MACE rate with TAXUS increased approximately 40 percent between two and three years (10.5 percent at two years vs. 14.9 percent at three years)*. MACE is an important composite clin
'/>"/>